Researchers compared lipoproteins and metabolites in the blood of COVID-19 patients and healthy subjects, revealing signs of multi-organ damage in patients that could someday help diagnose and treat COVID-19.

Beijing Bohui Innovation Biotechnology acquires a total of 50% of ABIOQUANT BIO-MEDCAL TECHNOLOGY with RMB 24 million in cash.

A-share spin-off listing set off a crazy trend recently. According to Securities Daily, till Aug. 13, exceeding 40 listed companies planned to spin-off listing.

According to 2019 China In Vitro Diagnosis Industry Report, the size of Chinese IVD market in 2019 exceeded RMB 90 billion (over US$ 12.8 billion), with a growth of about 15%. Among them, imported products account for about 55% in the overall market.

Sept. 4th, the much-awaited safety and immunogenicity data of two early phase clinical trials of Gam-COVID 19 have been published in the medical journal The Lancet, and experts have been quick to provide their thoughts on the data.

A blood test on hospital admission showing the presence or absence of SARS-CoV-2 can identify patients at a high risk of severe COVID-19.

In Biomicrofluidics, by AIP Publishing, scientists report a membrane-based invention that can concentrate the virus content of a sample of urine or saliva, allowing it to be detected.

Researchers have demonstrated a prototype of a rapid COVID-19 molecular test and a simple-to-use, portable instrument for reading the results with a smartphone in 30 minutes.

Researchers report that tiny packages of materials released by tumors, called EVPs (extracellular vesicles and particles), may serve as biomarkers for detecting a number of different types of cancer in the early stages.

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s ongoing efforts to fight COVID-19.

A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year.

Researchers reporting in ACS Nano have developed a prototype device that non-invasively detected COVID-19 in the exhaled breath of infected patients.

The findings, published in the Journal of Medical Microbiology, show the rapid molecular test called N1-STOP-LAMP, is 100% accurate in diagnosing samples containing SARS-CoV-2 at high loads.

A novel flavivirus identification test that is both fast and sensitive has been validated in Brazil by Mariana Sequetin Cunha and collaborators at the Adolfo Lutz Institute.

University of Queensland researchers have developed biosensors that use nanoengineered porous gold which more effectively detect early signs of disease, improving patient outcomes.